CY1123927T1 - Παραγωγο 5-μεθυλ-6-φαινυλ-4,5-διυδρο-2η-πυριδαζιν-3-ονης για τη θεραπεια ογκων του εγκεφαλου - Google Patents
Παραγωγο 5-μεθυλ-6-φαινυλ-4,5-διυδρο-2η-πυριδαζιν-3-ονης για τη θεραπεια ογκων του εγκεφαλουInfo
- Publication number
- CY1123927T1 CY1123927T1 CY20211100155T CY211100155T CY1123927T1 CY 1123927 T1 CY1123927 T1 CY 1123927T1 CY 20211100155 T CY20211100155 T CY 20211100155T CY 211100155 T CY211100155 T CY 211100155T CY 1123927 T1 CY1123927 T1 CY 1123927T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- pyridazine
- dihydro
- phenyl
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει έναν παράγοντα για τη θεραπεία κακοήθους όγκου, που περιλαμβάνει μια ένωση του τύπου (1) όπου τα R1 έως R4 είναι άτομο υδρογόνου, αλογόνο, ή κ.τ.λ., το Υ είναι προαιρετικώς υποκατεστημένη αλκυλενο ομάδα ή κ.τ.λ.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016042535 | 2016-03-04 | ||
| PCT/JP2017/008246 WO2017150654A1 (en) | 2016-03-04 | 2017-03-02 | 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123927T1 true CY1123927T1 (el) | 2022-05-27 |
Family
ID=58347859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100155T CY1123927T1 (el) | 2016-03-04 | 2021-02-24 | Παραγωγο 5-μεθυλ-6-φαινυλ-4,5-διυδρο-2η-πυριδαζιν-3-ονης για τη θεραπεια ογκων του εγκεφαλου |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10611731B2 (el) |
| EP (1) | EP3423440B9 (el) |
| JP (1) | JP6596595B2 (el) |
| KR (1) | KR102350772B1 (el) |
| CN (1) | CN108779076B (el) |
| AU (2) | AU2017226674B2 (el) |
| CA (1) | CA3015331A1 (el) |
| CY (1) | CY1123927T1 (el) |
| DK (1) | DK3423440T3 (el) |
| EA (1) | EA036423B1 (el) |
| ES (1) | ES2862177T3 (el) |
| HR (1) | HRP20210395T1 (el) |
| HU (1) | HUE053358T2 (el) |
| IL (1) | IL261225B (el) |
| LT (1) | LT3423440T (el) |
| MX (1) | MX2018010535A (el) |
| MY (1) | MY196801A (el) |
| NZ (1) | NZ745688A (el) |
| PH (1) | PH12018501873A1 (el) |
| PL (1) | PL3423440T3 (el) |
| PT (1) | PT3423440T (el) |
| RS (1) | RS61593B1 (el) |
| SA (1) | SA518392275B1 (el) |
| SG (1) | SG11201807146SA (el) |
| SI (1) | SI3423440T1 (el) |
| TW (1) | TWI731041B (el) |
| WO (1) | WO2017150654A1 (el) |
| ZA (1) | ZA201805791B (el) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7104588B2 (ja) * | 2017-09-01 | 2022-07-21 | 大塚製薬株式会社 | ５－メチル－６－フェニル－４，５－ジヒドロ－２ｈ－ピリダジン－３－オン誘導体を含有する悪性腫瘍治療剤 |
| WO2020157194A1 (en) * | 2019-02-01 | 2020-08-06 | Bayer Aktiengesellschaft | 1,2,4-triazin-3(2h)-one compounds for the treatment of hyperproliferative diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63145272A (ja) * | 1986-12-09 | 1988-06-17 | Morishita Seiyaku Kk | ４，５−ジヒドロ−６−（４−置換フエニル）−３（２ｈ）−ピリダジノン誘導体 |
| US5100892A (en) * | 1990-11-13 | 1992-03-31 | Glaxo Inc. | Dihydropyridine vasodilator agents |
| US5563143A (en) * | 1994-09-21 | 1996-10-08 | Pfizer Inc. | Catechol diether compounds as inhibitors of TNF release |
| CN1136197C (zh) * | 1996-05-30 | 2004-01-28 | 霍夫曼-拉罗奇有限公司 | 新的哒嗪酮衍生物 |
| CA2588949A1 (en) * | 2004-11-30 | 2006-06-08 | Artesian Therapeutics, Inc. | Compounds with mixed pde-inhibitory and .beta.-adrenergic antagonist or partial agonist activity for treatment of heart failure |
| EP2168959A1 (en) | 2007-06-19 | 2010-03-31 | Kyorin Pharmaceutical Co., Ltd. | Pyridazinone derivative and pde inhibitor containing the same as active ingredient |
| CN101537006B (zh) | 2008-03-18 | 2012-06-06 | 中国科学院上海药物研究所 | 哒嗪酮类化合物在制备抗肿瘤药物中的用途 |
| EP2970145B1 (en) * | 2013-03-11 | 2020-05-06 | The Broad Institute, Inc. | Compounds and compositions for the treatment of cancer |
-
2017
- 2017-03-02 CN CN201780013870.4A patent/CN108779076B/zh active Active
- 2017-03-02 HU HUE17711366A patent/HUE053358T2/hu unknown
- 2017-03-02 EP EP17711366.9A patent/EP3423440B9/en active Active
- 2017-03-02 DK DK17711366.9T patent/DK3423440T3/da active
- 2017-03-02 AU AU2017226674A patent/AU2017226674B2/en active Active
- 2017-03-02 MY MYPI2018703021A patent/MY196801A/en unknown
- 2017-03-02 KR KR1020187028010A patent/KR102350772B1/ko active IP Right Grant
- 2017-03-02 RS RS20210193A patent/RS61593B1/sr unknown
- 2017-03-02 MX MX2018010535A patent/MX2018010535A/es unknown
- 2017-03-02 SG SG11201807146SA patent/SG11201807146SA/en unknown
- 2017-03-02 SI SI201730668T patent/SI3423440T1/sl unknown
- 2017-03-02 PL PL17711366T patent/PL3423440T3/pl unknown
- 2017-03-02 WO PCT/JP2017/008246 patent/WO2017150654A1/en active Application Filing
- 2017-03-02 ES ES17711366T patent/ES2862177T3/es active Active
- 2017-03-02 CA CA3015331A patent/CA3015331A1/en active Pending
- 2017-03-02 TW TW106106813A patent/TWI731041B/zh active
- 2017-03-02 JP JP2018544577A patent/JP6596595B2/ja active Active
- 2017-03-02 NZ NZ745688A patent/NZ745688A/en unknown
- 2017-03-02 PT PT177113669T patent/PT3423440T/pt unknown
- 2017-03-02 US US16/081,260 patent/US10611731B2/en active Active
- 2017-03-02 EA EA201891987A patent/EA036423B1/ru not_active IP Right Cessation
- 2017-03-02 LT LTEP17711366.9T patent/LT3423440T/lt unknown
-
2018
- 2018-08-19 IL IL261225A patent/IL261225B/en unknown
- 2018-08-26 SA SA518392275A patent/SA518392275B1/ar unknown
- 2018-08-29 ZA ZA2018/05791A patent/ZA201805791B/en unknown
- 2018-09-03 PH PH12018501873A patent/PH12018501873A1/en unknown
-
2020
- 2020-02-12 US US16/788,894 patent/US20200181092A1/en not_active Abandoned
-
2021
- 2021-02-22 AU AU2021201135A patent/AU2021201135B2/en active Active
- 2021-02-23 US US17/182,549 patent/US20210171472A1/en active Pending
- 2021-02-24 CY CY20211100155T patent/CY1123927T1/el unknown
- 2021-03-08 HR HRP20210395TT patent/HRP20210395T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122111T1 (el) | Παραγωγα πολυκυκλικου αμιδιου ως cdk9 αναστολεις | |
| CY1123475T1 (el) | Αναστολεις της ειδικης για λυσινη απομεθυλασης-1 | |
| CY1124173T1 (el) | Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες | |
| CY1123988T1 (el) | Ενωση πυριδινης | |
| CY1118572T1 (el) | Παραγωγο κυκλοαλκανιου | |
| CY1119585T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινης | |
| CY1123994T1 (el) | Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4 | |
| CY1123353T1 (el) | Καινοφανης ενωση συμπυκνωμενης πυριμιδινης ή αλας εξ αυτης | |
| CY1125127T1 (el) | Αναστολεις λυσινης ειδικης απομεθυλασης-1 | |
| CY1124187T1 (el) | Ετεροκυκλικα αμιδια ως αναστολεις κινασης | |
| CY1124514T1 (el) | Ενωσεις [1,2,4]τριαζολο[1,5-α]πυριδινυλ-υποκατεστημενης ινδολης | |
| CY1122279T1 (el) | Ενωσεις ναφθυριδινης αναστολεις κινασης jak | |
| CY1122340T1 (el) | Αντιπολλαπλασιαστικες ενωσεις και μεθοδοι χρησης αυτων | |
| CY1121694T1 (el) | Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4 | |
| CY1123154T1 (el) | Παραγοντας ενισχυσης της επιδρασης αποκαταστασης μετα απο νευρικη βλαβη που περιλαμβανει ενα παραγωγο αλκυλαιθερα ή ενα αλας αυτου | |
| CY1123666T1 (el) | Φαρμακευτικες ενωσεις | |
| CY1122521T1 (el) | ΕΝΩΣΗ (6S,9AS)-N-BENZYΛO-6-((4-YΔPOΞYΦAINYΛO)ΜΕΘΥΛΟ)-4,7-ΔΙΟΞΟ-8-((6-(3-(ΠΙΠΕΡΑΖΙΝ-1-ΥΛΟ)ΑΖΕΤΙΔΙΝΟ-1-ΥΛΟ)ΠΥΡΙΔΙΝ-2-ΥΛΟ)ΜΕΘΥΛΟ)-2-(ΠΡΟΠ-2-ΕΝ-1-ΥΛΟ)-OKTAΫΔPO-lH-ΠYPAZINO(2,l-C)(l,2,4)ΤΡΙΑΖΙΝΟ-1-ΚΑΡΒΟΞΑΜΙΔΙΟΥ | |
| EA201791563A1 (ru) | Замещенные нуклеозидные производные, полезные в качестве агентов против рака | |
| MX365590B (es) | Metodos para preparar 6-(aril o heteroaril)-1,3,5-triazin-2,4-diol es y 6-(aril o heteroaril)-1,3,5-triazin-2,4-diaminas. | |
| UY38296A (es) | Derivados de 3–(5–amino–1–oxoisoindolin–2–il)piperidin–2,6–diona y sus usos | |
| BR112018070163A2 (pt) | compostos de aminopurina substituída, composições e métodos de tratamento | |
| WO2016105528A3 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| CY1121677T1 (el) | Ενωσεις διμεθυλοβενζοϊκου οξεος | |
| CY1123927T1 (el) | Παραγωγο 5-μεθυλ-6-φαινυλ-4,5-διυδρο-2η-πυριδαζιν-3-ονης για τη θεραπεια ογκων του εγκεφαλου | |
| UY38767A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados con braf |